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ABSTRACT 
Background: Tinnitus is a common symptom in audiology and neurology 
patients. Controversial data have been reported in the literature about the 
prevalence of tinnitus in hypertensive patients, whereas its relationship with 
the extent of blood pressure (BP) control has not been substantially explored. 
Objective: The aim of this study was to determine the prevalence of tinnitus 
in hypertensive patients, and the impact of different antihypertensive drugs on 
the incidence of tinnitus in these patients. 
Methods: This prospective, single-blind, observational study was conducted 
at the Hypertension Clinic, St. Orsola-Malpighi Hospital, Bologna, Italy. Patients 
aged 18 to 75 years with uncontrolled hypertension and receiving antihyperten- 
sire therapy were enrolled. Patients were asked to complete a standardized 
questionnaire to assess the presence, frequency, and duration of tinnitus and 
the apparent effect of their antihypertensive treatment on it. Patients consid- 
ered by the investigator to have tinnitus, regardless of their audiologic ondi- 
tion, underwent a complete clinical cardiovascular examination, including 
supine systolic BP (SBP) and diastolic BP measurement and standard 12-lead 
electrocardiography. Twelve-hour ambulatory BP monitoring was also per- 
formed, and patients were asked to record, using patient diaries, times of the 
onset and resolution of tinnitus that occurred during those 12 hours. From 
these data, correlations between the onset of tinnitus and BP were calculated. 
Results: A total of 476 patients participated in the study (283 men, 193 wom- 
en). Of these, 84 (17.6%) patients reported occasional or prolonged sponta- 
neous tinnitus, whereas 392 (82.4%) reported no tinnitus. The incidence of tin- 
nitus was significantly higher in patients receiving diuretics (72/265 [27.2%]) 
compared with those receiving angiotensin II receptor blockers (5/37 [13.5%]), 
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c~-blockers (12/55 [21.8%]), or 3-hydroxy-3-methylglutaryl coenzyme A reduc- 
tase inhibitors (9/73 [12.3%]) (all, P < 0.05). Mean (SD) SBP was significantly 
higher in patients without innitus compared with those with it (143.2 [ 11.1] vs 
140.6 [10.3] mm Hg; P < 0.005). In 10 (11.9%) patients with tinnitus, the onset 
was correlated with a sudden decrease in SBP (<140 mm Hg). 
Conclusions: In this study of tinnitus in patients receiving antihypertensive 
therapy, tinnitus was found in 17.6% of patients. Tinnitus was associated with 
the use of diuretics and with low SBP. Further studies are needed. (Curr TherRes 
Clin Exp. 2005;66:420-432) Copyright © 2005 Excerpta Medica, Inc. 
Key words: tinnitus, hypertension, diuretics, angiotensin II receptor block- 
ers, a-blockers, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 
INTRODUCTION 
Tinnitus, a nonspecific symptom often described as a ringing or roaring in the 
ear, is a major clinical problem, not only in otology but also in routine clinical 
practice, because the uncertainties about its etiology and pathogenesis make it 
difficult o treat. In 1 study, tinnitus was associated with hearing loss of variable 
origin in 93% of cases. I According to different hypotheses, it can be triggered by 
central and/or peripheral mechanisms. Tinnitus is common in audiology and 
neurology patients. The subjective perception of the condition is largely 
dependent on its intensity, which is often described as varying with different 
situations of daily life. The worldwide prevalence oftinnitus, based on standard 
subjective valuation, ranges from 6.6% to 80.0%. 2-3 The prevalence is reported 
to be higher in elderly patients 2 and in workers exposed to industrial noise 1 
compared with the general population. Approximately 40 million (~ 15%) people 
in the United States are affected by tinnitus, with -10 million (~25%) having 
moderate to severe tinnitus. 3 According to the British Tinnitus Association, 4 the 
prevalence of tinnitus in the United Kingdom is -10%, with 8% of the affected 
population having severe tinnitus. In a survey of >50,000 patients in Spain, 5 
~20% had experienced tinnitus at least once. 
Despite evidence suggesting that tinnitus is not of only cochlear origin, 
cochlear involvement is frequently associated with other possible causes. 
Tinnitus has been associated with several dysfunctions of the inner ear, 
although most of these dysfunctions do not cause hearing impairment. 3,4In par- 
ticular, tinnitus might develop in response to organic (eg, toxic compounds, 
cochlear lesions, ototoxic drugs) or functional mechanisms that might impair 
sensorineural perception at the cochlear level. Despite the complexity of the 
mechanisms of tinnitus, which certainly involve a central nervous ystem path- 
way, 5 systemic blood pressure (BP) might have a prominent role in some 
patients. Based on a MEDLINE search (key terms: hypertension, hypotension, 
blood pressure, and tinnitus; years: 1970-2005), a limited number of studies have 
investigated the prevalence of tinnitus in hypertensive patients without iden- 
tifying a definite increase in the incidence of tinnitus in these patients. 6-8 
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Conversely, a transient decrease in systemic BP could enhance the intensity of 
individual symptoms. 5-7 This issue was investigated using ambulatory BP moni- 
toring (ABPM) in 23 untreated healthy patients with sensorineural hearing loss 
(SNHL), in whom the incidence of persistent hypotension (>2 consecutive BP 
measurements <105/<60 mm Hg) was significantly higher compared with 20 age- 
and sex-matched asymptomatic controls. 9 Based on results from 1 study in 
which a sudden reduction in BP in the presence of hypertension caused transi- 
tory SNHL that was likely attributable to hypoperfusion of the inner-ear circu- 
lation in patients with malignant hypertension, 1° a decrease in systemic BP 
would lead to circulatory impairment of the cochlea, which could disturb the 
sensorineural response, leading to the onset of tinnitus. Furthermore, based on 
the observation i 1 study that sympathectomy reduced the incidence of tinni- 
tus in normotensive and spontaneously h pertensive rats, 11 the same hypoten- 
sive response would elicit a baroreceptor response with reflex activation of the 
sympathetic nervous ystem that might promote the development of tinnitus. 
However, despite evidence in the literature, a clear relationship between tinni- 
tus and high BP in the general hypertensive population has not been definitely 
established. 
The onset of tinnitus might be an adverse event in patients treated with 
different drugs, including antibiotics, salicylate, and cisplatinumJ 2 In most 
patients, the presence of tinnitus is the consequence of toxic damage of the 
labyrinth, even if a vascular mechanism resulting from cochlear hypoperfusion 
cannot be excluded in patients treated with cardiovascular d ugs. 
The aim of this study was to determine the overall prevalence oftinnitus, and 
the association between the rate of tinnitus and the different antihypertensive 
drugs used in a large cohort of hypertensive patients receiving antihyperten- 
sire treatment. 
PATIENTS AND METHODS 
This prospective, single-blind, observational study was conducted at the 
Hypertension Clinic, St. Orsola-Malpighi Hospital, Bologna, Italy. The study pro- 
tocol was approved by the ethics committee at the hospital, and all patients 
provided written informed consent to participate before inclusion in the study. 
Inclusion and Exclusion Criteria 
From September 1,2004, to November 30, 2004, we enrolled a cohort of 481 
consecutive, unselected, treated hypertensive patients who were referred 
for the first time to the clinic for a clinical and therapeutic assessment 
including poor BP control. The cohort included male and female patients 
aged 18 to 75 years with mild to moderate hypertension (European Society of 
Hypertension-European Society of Cardiology [ESH-ESC] 13 grade I or II 
[systolic/diastolic BP (SBP/DBP), _>140/_>90 mm Hg]) who were receiving anti- 
hypertensive treatment at the time of enrollment. Patients could also be receiv- 
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ing a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor 
and/or antithrombotic agent. 
Patients were excluded if they had known secondary causes of hypertension, 
had exposure to noise of __.85 dB for 8 h/d for at least 1 month, had a history of 
otologic disorders or previous episodes of hearing impairment or disturbances, 
and/or were unable to follow the study protocol. Patients were also excluded if
they were pregnant, had ~1 major concomitant disease, and/or were receiving 
treatment with drugs other than the study drugs. 
Procedures 
Treatments 
In patients whose BP values were elevated espite receiving antihyperten- 
sive therapy, an additional antihypertensive drug was added to the existing regi- 
men on completion of study procedures. HMG-CoA reductase inhibitors and 
antithrombotic drugs were included among the studied treatments because 
they are commonly used in hypertensive patients and might favorably affect 
microcirculation, thereby interfering with the mechanisms possibly involved in 
the onset and recurrence of tinnitus. 
Tinnitus Self-Assessment 
On the morning before the first study visit, patients were instructed to complete 
a standard, internally validated questionnaire to assess the presence, frequency, 
and duration of tinnitus. The results of the questionnaire were reviewed by a 
trained, experienced audiologist to confirm the presence or absence of tinnitus. 
Clinical Evaluation 
Patients considered to have tinnitus (in the opinion of the audiologist who 
assessed responses on the questionnaire) regardless of their audiologic ondi- 
tion assessed using clinical history and additional audiometric examination 
where appropriate, underwent a complete cardiovascular examination, includ- 
ing BP measurement and standard 12-lead electrocardiography. Resting supine 
and standing BPs were measured in the dominant arm using a standard mer- 
cury sphygmomanometer to the nearest 2 mm Hg. The mean of 3 consecutive 
BP measurements recorded at 1-minute intervals was used. The mean of 3 rest- 
ing supine heart rate measurements al o was used. The investigators who per- 
formed clinical evaluations were blinded to the results of the questionnaire. 
Ambulatory Blood Pressure Monitoring 
The next day, 12-hour ABPM (Spacelab 90207 version 1.03.16, Spacelabs 
Medical, Inc., Issaquah, Washington) was conducted to assess the relationship 
between the onset of tinnitus and the extent of BP changes. On ABPM, BP was 
measured at 15-minute intervals from 9 AM (+1 hour) to 9 PM (+1 hour). Because 
the sphygmomanometer did not show the measured values, patients were 
blinded to the BP measurements. During ABPM, patients were asked to record 
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the times of the onset and resolution of tinnitus using a patient diary. To better 
define the relationship between the onset of tinnitus and the occurrence of sud- 
den changes in BP, patients were also instructed to immediately push a "start" 
button on the monitor whenever they began to experience tinnitus. 
Statistical Analysis 
Two-way analysis of variance was used to compare the continuous variables 
between the different populations of patients at baseline. For categoric vari- 
ables, the Z 2 test was used, with Yates correction when appropriate. The sta- 
tistical approach was 2-fold. The first step was a descriptive analysis of data 
finalized to assess the rate of tinnitus within the hypertensive population and 
to compare it with that described by other surveys in the same field. The sec- 
ond step was based on the possibility of quantifying the differences (if any) 
between the subgroups of patients treated with the different drugs, and the 
study power was calculated based on subgroup size and on a level of signifi- 
cance of 0.05 for a between-group difference of 11% (2%). It was calculated that 
a subgroup size of at least 35 patients was needed. Statistical analysis was carried 
out using SPSS version 9.0.6 (SPSS Inc., Chicago, Illinois). Results are expressed as 
mean (SD). 
RESULTS 
Four hundred eighty-one patients were enrolled in the study, and 476 patients 
(283 men, 193 women) provided responses on the questionnaire that made 
them eligible for inclusion in the study. At baseline, the mean (SD) duration of 
hypertension was 9.1 (3.40) years, and the mean (SD) duration of treatment was 
6.2 (0.2) years (range, 6 months - 9 years). Hypertension was adequately 
treated, based on ESH-ESC guidelines 13(<140/<90 mm Hg), in 159 (33.4%) 
patients, whereas BP (particularly SBP) was not controlled in the remainder 
of the population (317 [66.6%]). Drug treatment was unchanged uring the 
6 months before the study in 395 (83.0%) patients, and 64 (13.4%) patients under- 
went only a minor dosage adjustment. 
There were significantly fewer patients with than without a history of occa- 
sional or continuous tinnitus (84 [17.6%] vs 392 [82.4%]; P < 0.00 l) (Table). The 
incidence of tinnitus was significantly higher in women compared with men 
(39/193 [20.2%] vs 45/283 [15.9%]; P < 0.05). Mean (SD) supine SBP was signifi- 
cantly lower in patients with tinnitus compared with patients without it (140.6 
[9.8] mm Hg vs 143.2 [10.9] mm Hg; P = 0.005), but this difference was not found 
with supine DBP (87.3 [7.2] mm Hg vs 88.7 [7.1] mm Hg). There were no signifi- 
cant differences between the 2 groups in age, prevalence of concomitant risk 
factors (ie, diabetes, dyslipidemia), or percentages of patients treated with anti- 
hypertensive drug therapy alone or in combination. The prevalence of tinnitus 
was comparable when the 2 populations were subclassified based on age 
groups (<30 years, 30-59 years, and >59 years) (Figure 1). 
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Table. Baseline characteristics of the study population (n = 476), by presence or 
absence of tinnitus. 
Characteristic Tinnitus No Tinnitus 
No. (%) of patients 84 (17.6) 392 (82.4)* 
Age, mean (SD), y 60.3 (11.2) 61.6 (7.1) 
Sex, no. (%) 
Male (n = 283) 45 (15.9) 238 (84.1) 
Female (n = 193) 39 (20.2) t 154 (80.0) 
HR (supine), mean (SD), bpm 67.6 (7.3) 68.2 (8.6) 
Blood pressure, mean (SD), mm Hg 
SBP 
Standing 139.7 (12.0) 143.6 (11.2) 
Supine 140.6 (10.1) 143.2 (11.2) 
DBP 
Standing 87.5 (6.1) 88.4 (6.0) 
Supine 87.3 (7.2){ 88.7 (7.1) 
Concomitant risk factors, no. (%) 
Dyslipidemia (n = 162) 30 (18.5) 1 32 (81.5) 
Diabetes (n = 110) 20 (18.2) 90 (81.8) 
Current antihypertensive treatment, no. (%) 
Monotherapy (n = 254) 43 (16.9) 211 (83.1) 
Combination therapy (n = 222) 41 (18.5) 181 (81.5) 
HR = heart rate; SBP = systolic blood pressure; DI3P = diastolic blood pressure. 
*P < 0.001 versus patients with tinnitus. 
~P < 0.05 versus male. 
{P = 0.05 versus patients without tinnitus. 
The prevalence of tinnitus was significantly higher in patients with uncon- 
trolled BP (_>140/_>90 mm Hg) compared with patients with adequate BP control 
(<140/<90 mm Hg) (Figure 2). Specifically, tinnitus was present in 11/94 (11.7%) 
male and 13/72 (18.1%) female patients with controlled BP compared with 
34/191 (17.8%) male and 26/121 (21.5%) female patients with uncontrolled BP 
(both, P < 0.01). Mean (SD) daytime systolic and diastolic ABPM values were 
slightly but significantly lower in patients with tinnitus compared with patients 
without it (130.5 {8.2]/83.9 {4.3] vs 134 {9.1]/87 [4.0] mm Hg; P< 0.005). In 10 of 
84 (11.9%) patients with tinnitus, the onset of symptoms was associated with a 
dramatic decrease in SBP that could be strictly related to the peak effect of the 
antihypertensive tr atment, as suggested by the individual data recorded in 2 dif- 
ferent patients, shown in Figure 3. 
Regarding the presence or absence of tinnitus in the study population in rela- 
tion to the distribution of antihypertensive, cholesterol-lowering, and antithrom- 
botic drugs, at baseline, 43/254 (16.9%) and 41/222 (18.5%) patients being treated 
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Figure 1. Prevalence of tinnitus in the hypertensive population by age group. No 
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Figure 2. Prevalence of tinnitus in the hypertensive population and extent of blood 
pressure (BP) control. *P < 0.01 versus uncontrolled BP. 
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Figure 3. Relationship between blood pressure decrease and occurrence of tinnitus in 
2 patients with hypertension. SBP = systolic blood pressure; DBP = diastolic 
blood pressure; ACE = angiotensin-converting enzyme; CCB = calcium channel 
blocker. 
with monotherapy and combination therapy, respectively, reported tinnitus; 
211/254 (83.1%) and 181/222 (81.5%) patients being treated with monotherapy 
and combination therapy, respectively, did not report tinnitus; these between- 
group differences were not significant (Table). 
Concerning the types of antihypertensive drugs used in the overall study 
population, 293 (61.6%) patients were treated with an angiotensin-converting 
enzyme inhibitor; 265 (55.?%), with a diuretic; 240 (50.4%), with a 0-blocker; 225 
(4?.3%), with a calcium channel blocker (CCB); 80 (16.8%), with an antithrom- 
botic drug (mainly acetylsalicylic acid [ASA]); 73 (15.3%), with an HMG-CoA 
reductase inhibitor; 55 (11.6%), with an co-blocker; and 37 (?.8%), with an 
angiotensin II receptor blocker (ARB). These different classes of antihyperten- 
sive drugs were used alone or in combination. The prevalence of tinnitus was 
significantly lower in patients treated with ARBs and R-blockers (5/3? [13.5%] 
and 12/55 [21.8%], respectively) compared with patients treated with diuretics 
(72/265 [27.2%]) (both, P < 0.05) (Figure 4). Moreover, tinnitus was more preva- 
lent in the patients treated with a diuretic compared with those treated with an 
HMG-CoA reductase inhibitor (72/265 [27.2%] vs 9/73 [12.3%]; P < 0.05), but not 
those treated with an antithrombotic drug (ASA) (15/80 [18.8%]). The doses of 
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Figure 4. Prevalence of t innitus and pharmacologic t reatment in the study popula- 
tion. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II 
receptor blockers; CCB = calcium channel blocker; HMG-CoA RI = 3-hydroxy- 
3-methylglutaryl coenzyme A reductase inhibitor. *P < 0.05 versus diuretics. 
the different drugs were included in the data analysis, and no differences were 
observed between patients with and without innitus (data not shown). 
DISCUSSION 
Tinnitus is a major clinical problem because it involves a large proportion of the 
general population and can significantly impair the quality of life and working 
attitude of affected individuals. The available data on the rate of tinnitus in 
the hypertensive population are still controversial. In the present study, we 
found that the prevalence of tinnitus in hypertensive patients was significantly 
higher in female patients and in those with lower office and ABPM SBP values. 
Conversely, the prevalence of tinnitus was significantly lower in patients 
treated with ARBs and c~-blockers. These findings upport he possible role of 
renin-angiotensin ystem (RAS) activation of the sympathetic nervous ystem 
in the pathogenesis of the disease. 
Other studies 9,14,15 support our findings, suggesting that the hypothesis that 
impaired vasomotor regulation of the peripheral vascular tree might be respon- 
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sible for intermittent labyrinthine functional damage in response to systemic 
BP decrease. In particular, in 11.9% of the population with tinnitus, ABPM 
showed a close temporal correlation between the time course of a decrease in 
BP and the onset of symptoms of tinnitus. The small proportion of patients 
showing such time dependency between the hypotensive response and the 
onset of symptoms does not rule out the possibility that a slower or persistent 
BP decrease could also affect the prevalence of tinnitus. Our data suggest only 
that in 11.9% of patients, the BP reduction per se might be responsible for the 
onset of tinnitus, whereas in the remainder of the population with tinnitus, the 
role of BP reduction might be additive to that of other causative factors (eg, ath- 
erosclerotic disease). This study did not address the relationship between the 
extent of BP decrease and the intensity of tinnitus. 
The perception of the intensity of tinnitus is rather subjective and is influ- 
enced strictly by the duration of episodes of tinnitus and the daily rate of tin- 
nitus. 3,4 Nonetheless, these data support the possibility that the onset or the 
enhanced intensity of tinnitus could result from a decrease in cochlear blood 
flow when BP decreases and vasomotor autoregulation is impaired, as occurs 
in patients with arterial hypertension. 16This negative mechanism might be 
dramatically enhanced by the concomitant activation of the sympathetic nerv- 
ous system elicited by stressful situations or by the administration ofvasodila- 
tory drugs, which could further reduce the autoregulatory mechanisms at the 
level of cochlear microcirculation. This mechanism could explain the dif- 
ferences we observed in the prevalence of tinnitus among the subgroups of 
hypertensive patients treated with different antihypertensive drugs. In partic- 
ular, we speculate that the administration of some CCBs, which elicit a reflex 
sympathetic activation in response to BP decrease, 17 or treatment with drugs 
that increase peripheral vascular tone (eg, [3-blockers) or activate the RAS 
might contribute to the development of tinnitus in the hypertensive popula- 
tion. Accordingly, we speculate that tinnitus might be related to an imbalance 
between the systemic and cochlear circulation, which in turn might be related 
to underlying pathophysiologic conditions and drug treatment. Two different 
observations seem to support this hypothesis. The first is our recent finding 
of unaffected audiologic conditions in nonotologic patients during general 
anesthesia with controlled systemic hypotension and pharmacologic sympa- 
thetic blockade. 18 The second is the finding in this study that the prevalence 
of tinnitus might be significantly reduced in patients being treated with drugs 
that block the vascular effects of either sympathetic activation (eg, c~-blockers) 
or tissue RAS (eg, ARBs). 
It seemed of some interest o consider the possibility that a pharmacologic 
treatment might be able to improve the autoregulatory properties of the vascu- 
lar cochlear system and protect it from the risk for hypoperfusion. Improved 
control of vascular function could be achieved with ARBs that reduce BP and 
vascular tone by preventing the vascular remodeling and the progression of 
atherosclerotic disease. 19 
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Regarding the possible role of HMG-CoA reductase inhibitors in hypertensive 
patients with tinnitus, these drugs could significantly improve ndothelial func- 
tion and reduce vascular tone and progression of atherosclerotic disease. 2°In 
addition, treatment with HMG-CoA reductase inhibitors down-regulates the 
expression of vascular angiotensin II type 1 receptors responsible for the vaso- 
constrictive and proatherogenic effects of angiotensin II.21 We speculate that 
treatment with HMG-CoA reductase inhibitors might favorably affect he struc- 
tural and functional properties of cochlear circulation and reduce the rate of 
tinnitus. Accordingly, we recently proposed the use of HMG-CoA reductase 
inhibitors for the treatment of sudden SNHL. 22 These additional preliminary 
data on the use of HMG-CoA reductase inhibitors in patients with tinnitus war- 
rant further investigation. 
Although it is possible that the rate of tinnitus might be regarded as an adverse 
effect of antihypertensive tr atment in response to an excessive BP decrease, this 
possibility does not affect he interpretation f the data and cannot explain the dif- 
ferences in the rate of tinnitus among patients treated with the different classes of 
drugs that have been shown to be largely comparable in terms of BP control. 13 
The present study had some limitations. First, it was not designed to pro- 
spectively assess the differences between the various classes of antihyper- 
tensive drugs in preventing the onset of tinnitus, which means that the lower 
rate of tinnitus observed in patients treated with some classes of antihyperten- 
sire drugs (eg, ARBs, ~-blockers, HMG-CoA reductase inhibitors), despite statis- 
tically significant between-group differences, could be due to chance and must 
be confirmed by prospective randomized trials. In addition to the relatively 
small number of patients included in the study, the differences in the size of the 
different subgroups reduces the overall power of the study, the results of which 
should be confirmed in a larger population of patients. 
Second, the study did not investigate any causal mechanism of tinnitus and 
simply provided evidence about the association between BP control and the 
onset of tinnitus. This simple association could mean that a third, unexplored 
mechanism could be separately involved in the BP decrease and the onset of 
tinnitus, thereby excluding the possibility of a direct causal role. The question- 
naire for the diagnosis of tinnitus was developed locally but was validated by 
an internal panel of experts based on international criteria for the definition and 
diagnosis of tinnitus. 3,4 Before the present study, the questionnaire was tested 
for many years in large populations of patients with tinnitus of different etiolo- 
gies, and the results were reported to be largely reproducible in the same pa- 
tient over time. 14 
CONCLUSIONS 
In this study of tinnitus in patients receiving antihypertensive therapy, tinnitus 
was found in 17.6% of patients. Tinnitus was associated with the use of diuret- 
ics and with low SBP. Further studies are needed. 
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